Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Astria Therapeutics, Inc. (ATXS : NSDQ)

• Company Description    Astria Therapeutics is a biopharmaceutical company which focuses on therapies to treat allergic and immunological diseases. The company's program include STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Astria Therapeutics, formerly known as Catabasis Pharmaceuticals Inc., is based in BOSTON. Number of Employees: 78

• Price / Volume Information    Yesterday's Closing Price: $12.51 Daily Weekly Monthly 20 Day Moving Average: 4,311,752 shares Shares Outstanding: 56.44 (millions) Market Capitalization: $706.00 (millions) Beta: 0.21 52 Week High: $12.72 52 Week Low: $3.56 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 50.54% 46.60% 12 Week 82.63% 75.06% Year To Date 39.93% 22.32%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 22 Boston Wharf Road 10th Floor - Boston,MA 02210 USA ph: 617-349-1971 fax: 617-273-2637 investors@astriatx.com http://www.astriatx.com

• General Corporate Information    Officers Jill C. Milne - President and Chief Executive Officer and Director Kenneth Bate - Chairman Noah Clauser - Chief Financial Officer and Treasurer Sunil Agarwal - Director Joanne Beck - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04635X102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 56.44 Most Recent Split Date: 8.00 (0.17:1) Beta: 0.21 Market Capitalization: $706.00 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.59 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.09 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.27 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -32.56% vs. Previous Quarter: 1.72% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -56.39 03/31/25 - -47.18 ROA 09/30/25 - - 06/30/25 - -36.08 03/31/25 - -31.26 Current Ratio 09/30/25 - - 06/30/25 - 14.89 03/31/25 - 17.39 Quick Ratio 09/30/25 - - 06/30/25 - 14.89 03/31/25 - 17.39 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 2.93 03/31/25 - 3.44 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 36.59 03/31/25 - 32.95

Powered by Zacks Investment Research ©